Jubilant Life Sciences Ltd

Regd. Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar-244 223 (U.P.)

Statement of Audited Results for the Quarter and Year ended 31st March,2013

(₹ in Lacs)

STAND ALONE RESULTS					Particulars	CONSOLIDATED RESULTS				
Quarter Ended			Year Ended			Quarter Ended			Year Ended	
March 31	December 31	March 31	March 31			March 31	December 31	March 31	March 31	
(Unaudited)			(Audited)			(Unaudited)			(Audited)	
2013	2012	2012	2013	2012		2013	2012	2012	2013	2012
					PART I					
					Income from operations					
84066	81083	69356	312485	261764	(a) Net sales/Income from operations (Net of excise duty)	138829	130181	117110	514299	425395
488	599	723	2145	2343	(b) Other Operating Income	375	458	3319	1796	4918
84554	81682	70079	314630	264107	**Total income from operations (net)**	139204	130639	120429	516095	430313
80558	72573	67773	284434	236145	**Expenses**	122478	110975	102675	437750	364604
41650	38302	31919	152858	123995	a) Cost of materials consumed	49610	43655	38094	180691	149469
4536	4967	5287	19174	24368	b) Purchase of traded goods	7582	7070	9096	30064	30534
2018	233	546	(2417)	(9326)	c) Change in inventories of finished goods, work-in-progress and traded goods	1656	2755	(1323)	(5750)	(18851)
8654	8655	8897	33791	27154	d) Power & fuel	9252	9183	9117	35855	28689
6867	6302	5349	24865	20723	e) Employee benefits expenses	24841	23834	21241	96218	83637
4139	3785	4283	15217	13200	f) Depreciation and amortization expenses	6952	6318	6619	25379	22065
12694	10329	11492	40946	36031	g) Other expenses	22585	18160	19831	75293	69061
3996	9109	2306	30196	27962	**Profit/(Loss) from operations before other income, finance cost and exceptional items**	16726	19664	17754	78345	65709
239	184	241	892	894	Other Income	745	356	471	1755	1529
4235	9293	2547	31088	28856	**Profit/(Loss) from ordinary activities before finance costs & exceptional items**	17471	20020	18225	80100	67238
4330	3959	4552	17117	15442	Finance costs	5907	5435	5855	23016	20959
(95)	5334	(2005)	13971	13414	**Profit/(Loss) from ordinary activities after finance costs but before exceptional items**	11564	14585	12370	57084	46279
2490	7260	(1742)	15252	18008	Exceptional items	9722	7098	14641	22970	34868
(2585)	(1926)	(263)	(1281)	(4594)	**Profit/(Loss) from ordinary activities before tax**	1842	7487	(2271)	34114	11411
233	588	15	3051	3497	Tax expense (Net)	4285	3536	3508	15236	6842
(2818)	(2514)	(278)	(4332)	(8091)	**Net Profit/(Loss) from ordinary activities after tax**	(2443)	3951	(5779)	18878	4569
-	-	-		-	Extraordinary items (net of tax expenses)	-	-	-	-	-
(2818)	(2514)	(278)	(4332)	(8091)	**Net Profit/(Loss) for the period**	(2443)	3951	(5779)	18878	4569
-	-	-		-	Share of Profit/(Loss) of Associate Company	-	-	-	-	-
-	-	-		-	Minority Interest	654	1282	574	3605	3113
(2818)	(2514)	(278)	(4332)	(8091)	**Net Profit/(Loss) after taxes, minority interest and share of profit/loss of associates**	(3097)	2669	(6353)	15273	1456
1593	1593	1593	1593	1593	Paid-up equity share capital (Face value per share ₹ 1)	1593	1593	1593	1593	1593
			184589	190117	Reserves (excluding revaluation reserve)				247842	224110
					Earnings per share before and after extraordinary items (Not annualized)					
(1.77)	(1.58)	(0.17)	(2.72)	(5.08)	**Basic (₹)**	(1.94)	1.68	(3.99)	9.59	0.91
(1.77)	(1.58)	(0.17)	(2.72)	(5.08)	**Diluted (₹)**	(1.94)	1.68	(3.99)	9.59	0.91
					PART II					
					PARTICULARS OF SHAREHOLDING					
					Public shareholding					
81166083	81166083	81166083	81166083	81166083	- Number of shares (₹ 1 each)	81166083	81166083	81166083	81166083	81166083
50.96	50.96	50.96	50.96	50.96	- Percentage of shareholding	50.96	50.96	50.96	50.96	50.96
					Promoters and promoter group Shareholding					
					a) Pledged/Encumbered					
-	3374000	3374000	-	3374000	- Number of shares	-	3374000	3374000	-	3374000
-	4.32	4.32	-	4.32	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	4.32	4.32	-	4.32
-	2.12	2.12	-	2.12	- Percentage of shares (as a % of the total share capital of the company)	-	2.12	2.12	-	2.12
					b) Non-Encumbered					
78115056	74741056	74741056	78115056	74741056	- Number of shares	78115056	74741056	74741056	78115056	74741056
100.00	95.68	95.68	100.00	95.68	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	95.68	95.68	100.00	95.68
49.04	46.92	46.92	49.04	46.92	- Percentage of shares (as a % of the total share capital of the company)	49.04	46.92	46.92	49.04	46.92
					Investor Complaints					
					Pending at the beginning of the quarter	Nil	Nil	Nil		
					Received during the quarter	7	18	10		
					Disposed of during the quarter	7	18	10		
					Remaining unresolved at the end of the quarter	Nil	Nil	Nil		

K.N. GUTGUTIA & Co. New Delhi CHARTERED ACCOUNTANTS

2

Jubilant Life Sciences Ltd.

Segment wise Revenue, Results and Capital Employed
(under Clause 41 of the Listing Agreement)

(₹ in Lacs)

STAND ALONE RESULTS					Particulars	CONSOLIDATED RESULTS				
Quarter Ended			Year Ended			Quarter Ended			Year Ended	
March 31	December 31	March 31	March 31			March 31	December 31	March 31	March 31	
(Unaudited)			(Audited)			(Unaudited)			(Audited)	
2013	2012	2012	2013	2012		2013	2012	2012	2013	2012
					Segment revenue					
19380	20308	16776	75646	56811	a. Pharmaceuticals	70196	66523	64626	265797	220131
65243	61437	53361	239252	207602	b. Life Sciences Ingredients	69077	64179	55861	250566	210488
84623	**81745**	**70137**	**314898**	**264413**	**Total**	**139273**	**130702**	**120487**	**516363**	**430619**
69	63	58	268	306	Less : Inter segment revenue	69	63	58	268	306
84554	**81682**	**70079**	**314630**	**264107**	**Net Sales/Income from operations**	**139204**	**130639**	**120429**	**516095**	**430313**
19380	20308	16776	75646	56811	a. Pharmaceuticals	70196	66523	64626	265797	220131
65174	61374	53303	238984	207296	b. Life Sciences Ingredients	69008	64116	55803	250298	210182
84554	**81682**	**70079**	**314630**	**264107**	**Total**	**139204**	**130639**	**120429**	**516095**	**430313**
					Segment results (profit(+)/loss(-) before tax and interest from each segment)					
1496	6004	2665	15248	10032	a. Pharmaceuticals	13035	15634	17192	59399	47088
6003	6525	1381	24756	25612	b. Life Sciences Ingredients	7193	7451	2301	28754	26302
7499	**12529**	**4046**	**40004**	**35644**	**Total**	**20228**	**23085**	**19493**	**88153**	**73390**
4330	3959	4552	17117	15442	Less : i Interest(Finance costs)	5907	5435	5855	23016	20959
5993	10680	(2)	25060	25690	ii. Other un-allocable expenditure(including exceptional items)	13168	11407	16380	33610	42549
(239)	(184)	(241)	(892)	(894)	iii. Un-allocable Income(including exceptional items)	(689)	(1244)	(471)	(2587)	(1529)
(2585)	**(1926)**	**(263)**	**(1281)**	**(4594)**	**Total Profit/(Loss) before tax**	**1842**	**7487**	**(2271)**	**34114**	**11411**
					Capital Employed (Segment assets less Segment liabilities)					
98684	100628	90475	98684	90475	a. Pharmaceuticals	449433	466006	417359	449433	417359
128987	137731	162059	128987	162059	b. Life Sciences Ingredients	168725	183446	174624	168725	174624
227671	**238359**	**252534**	**227671**	**252534**	**Total capital employed in segments**	**618158**	**649452**	**591983**	**618158**	**591983**
263705	248775	253947	263705	253947	Add: Un-allocable corporate assets less liabilities	49050	36018	43880	49050	43880
491376	**487134**	**506481**	**491376**	**506481**	**Total capital employed in the Company**	**667208**	**685470**	**635863**	**667208**	**635863**

2

K.N. GUTGUTIA & CO. New Delhi CHARTERED ACCOUNTANTS

Jubilant Life Sciences Ltd
Regd. Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar-244 223 (U.P.)

Statement of Assets And Liabilities

(₹ in Lacs)

STAND ALONE		Particulars	CONSOLIDATED	
As at March 31 (Audited)	As at March 31 (Audited)		As at March 31 (Audited)	As at March 31 (Audited)
2013	2012		2013	2012
		EQUITY AND LIABILITIES		
		Shareholders' Funds		
1593	1593	a) Share capital	1593	1593
184589	190117	b) Reserves & surplus	247842	224110
-	-	c) Money received against share warrants	-	-
186182	191710	**Sub-total- Shareholders' funds**	249435	225703
-	-	**Share application money pending allotment**	-	-
-	-	**Minority interest**	11154	6895
		Non-current liabilities		
200838	242221	a) Long-term borrowings	246881	283992
24193	21141	b) Deferred tax liabilities(Net)	32407	22403
-	-	c) Other long term liabilities	81	76
22735	15689	d) Long-term provisions	23797	16970
247766	279051	**Sub-total- Non-current liabilities**	303166	323441
		Current liabilities		
63256	48473	a) Short-term borrowings	91880	76707
93477	70670	b) Trade payables	105622	83699
47129	18679	c) Other current liabilities	67367	49955
11360	8835	d) Short-term provisions	14573	10918
215222	146657	**Sub-total- Current liabilities**	279442	221279
649170	617418	**TOTAL EQUITY AND LIABILITIES**	843197	777318
		ASSETS		
		Non-current assets		
239884	225903	a) Fixed assets	372779	354517
-	-	b) Goodwill on consolidation	167656	160055
197851	193802	c) Non-current investments	2561	1920
-	-	d) Deferred tax assets(net)	5008	1029
45324	46322	e) Long-term loans and advances	29392	29968
22	37	f) Other non-current assets	88	97
483081	466064	**Sub-total- Non-current assets**	577484	547586
		Current assets		
-	2170	a) Current investments	-	-
61121	59333	b) Inventories	111492	102022
39325	40382	c) Trade receivables	71002	65269
25588	20283	d) Cash & bank balances	35605	26682
34124	27495	e) Short-term loans and advances	35252	31260
5931	1691	f) Other current assets	12362	4499
166089	151354	**Sub-total- Current assets**	265713	229732
649170	617418	**TOTAL ASSETS**	843197	777318

K.N. GUTGUTIA & CO. New Delhi CHARTERED ACCOUNTANTS

2

Notes:

1. The Board has recommended a dividend of ₹ 3 per equity shares of ₹ 1 amounting to ₹ 5590 lacs, subject to approval in the Annual General Meeting.

2. The Company has opted for accounting of exchange difference arising on reporting of long term monetary items under Clause 46 A of AS 11 "The Effects of Changes in Foreign Exchange Rates" . Accordingly exchange differences both in standalone and consolidated results amounting to ₹ 1756 lacs for Q4-FY 2013 and ₹ 6316 lacs for FY 2013 has been amortized during the year. The accumulated debit balance as on 31st March, 2013 in Foreign Currency Monetary Items Translation Difference Account (FCMITDA) ₹ 6754 lacs, and under Fixed Assets/ Capital Work in Progress ₹ 1174 lacs, is to be amortized over the balance life of loans and assets respectively.

3. The company has applied hedge accounting in respect of certain transactions including forward contracts under Accounting Standard 30 issued by the Institute of Chartered Accountants of India and the credit balance in hedge reserve(Net) as at 31st March, 2013 is ₹ 5365 lacs (Consolidated ₹ 5479 lacs).

4. Exceptional items include :

i) Amortization of Foreign Currency Monetary Item Translation Difference Account-loss/(gain) ₹ 1756 lacs (Consolidated ₹ 1756 lacs) for Q4-FY 2013 and ₹ 6316 lacs (Consolidated ₹ 6316 lacs) for FY 2013.

ii) Mark to Market in respect of Currency & Interest rate swap contracts at the year end including ineffective portion of hedged forward contracts resulting in loss/(gain) amounting to ₹ 62 lacs (Consolidated ₹ 277 lacs) for Q4 FY 2013 and ₹ 8264 lacs (Consolidated ₹ 8391 lacs) for FY 2013.

iii) Write off of Intangible assets including products under development amounting to ₹ 556 lacs (Consolidated ₹ 6265 lacs) for Q4 and FY 2013.

iv) Others(net) includes Surplus on sale/discard of assets, one time legal expenses and inventory write down etc. amounting to ₹ 116 lacs (Consolidated ₹ 1424 lacs) for Q4 FY- 2013 and ₹ 116 lacs (Consolidated ₹ 1998 lacs) for FY- 2013.

5. Tax Expenses are net after considering the Deferred Tax charge/credit and MAT Credit Entitlement . The deferred tax charge for the period/ year include the impact of additional charge due to change in the surcharge rate

6. The figures of the last quarter are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year .

7. The above Audited Financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 7th May, 2013.

For Jubilant Life Sciences Ltd.

Shyam S Bhartia
Chairman & Managing Director

Place : Noida

Dated : 7th May, 2013

K.N. GUTGUTIA & CO. New Delhi CHARTERED ACCOUNTANTS